New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors. Results from the study were published in Cancer Immunology Research. It shows the potential for durable responses, laying the groundwork for future clinical trials and a possible new standard of care. 

Certain breast cancer therapies, while lifesaving, can also place stress on the heart, raising important questions about who might benefit from closer monitoring. But does every breast cancer survivor need to see a cardiologist?

The findings of this cohort study suggest that facility-based colorectal cancer screening among adults ages 45 to 49 increased nearly 10-fold following U.S. Preventive Services Task Force (USPSTF) guideline changes, far exceeding growth among those ages 50 to 75. This rapid adoption highlights early implementation by practitioners and patients. Although screening rates among adults ages 50 to 75 increased during the study period, the accelerated growth among those ages 45 to 49 reflected guideline integration into facility practices. 

Researchers discovered that different genetic drivers of leukemia use the same compartments inside the cell nucleus to keep cancer growing. The finding points to a shared physical target that could inspire new kinds of treatments.

The American Society for Radiation Oncology (ASTRO) recently announced the three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer (SCLC) Therapy Challenge, which supports research that will improve therapies and outcomes for patients with limited-stage SCLC through the integration of consolidation immunotherapy and emerging radiation therapy techniques. 

A pair of new studies examines two aspects of the colon cancer screening process: the preferences of patients and physicians for all currently available colorectal cancer screening options, and the impact of a 2023 federal policy change that eliminated out of pocket costs for those who get an abnormal result on a home-based stool test and then need a colonoscopy. 

Researchers have uncovered a promising cancer treatment strategy by targeting a mitochondrial protein called peroxiredoxin-3 (PRX3). PRX3 normally acts as a cleanup system inside cancer cells, breaking down hydrogen peroxide before it becomes toxic. The team discovered a compound fragment that binds to PRX3 and switches it off, causing hydrogen peroxide to accumulate beyond the cell’s tolerance. This surge in oxidative stress overwhelms cancer cells, while sparing healthy ones, offering a novel approach to therapy that flips the traditional model of reducing stress into one that exploits cancer’s vulnerability.

RTOG Foundation, a non-profit organization which conducts clinical trials designed to discover more effective cancer therapies, recently opened a new trial RTOG 3523, also known as the “MOMENTUM-1” study, testing the radioactive drug [¹⁷⁷Lu]Lu-DOTA-TATE (hereafter referred to as ¹⁷⁷Lu-Dotatate) in adult who have progressive intracranial grade 1-3 meningioma.

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection of slow-growing cancers that are unlikely to affect a patient’s lifespan, associated with PSA screening. To address this concern, the researchers advocate the development of risk-based screening.